Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3c2490060f1c8f7ba6135e860c6f3c7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65926bde90440f3178ef534c66bd7ce8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5e646b53d2eeeac8fed30ef7108abcb9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c126295a93f3489471937164efafeb46 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2330-51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-531 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
filingDate |
2010-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2013-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fb54ed46d052b3c8f5f667ce7fbda8b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c960156656df8b13d7da4cf9be27e86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ec4061c651ab8d69bbc8128dbf27165 |
publicationDate |
2013-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8361983-B2 |
titleOfInvention |
Therapeutic RNA interference technology targeted to the PDX-1 oncogene in PDX-1 expressing neuroendocrine tumors |
abstract |
A bifunctional shRNA-based composition and methods for knocking down the expression of the PDX-1 oncogene in target cells is described herein. The invention also provides methods to deliver the shRNA-containing expression vectors to target tissues overexpressing the PDX-1 oncogene. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9133459-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9914977-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9695422-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013084331-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9790518-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400170-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10253331-B2 |
priorityDate |
2009-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |